Literature DB >> 14507232

Botulinum toxin A (Botox Cosmetic): a review of its use in the treatment of glabellar frown lines.

James E Frampton1, Stephanie E Easthope.   

Abstract

Botox Cosmetic (Botox) is a formulation of the neuromuscular blocking agent botulinum toxin type A (BTX-A). When injected into hyperactive corrugator superciliaris and/or procerus muscles of the face that predominantly control frowning, Botox produces a transient (3- to 6-month), dose-dependent localized muscle weakness, resulting in a temporary improvement in glabellar frown lines ('brow furrows'). After a decade of successful 'off-label' use, the efficacy and tolerability of Botox (total dose 20 biological units) in the treatment of glabellar frown lines have been demonstrated in two identical, large, multicenter, randomized, double-blind, placebo-controlled pivotal trials in a total of 537 subjects, mostly women, with moderate or severe glabellar lines during facial animation. Based both on subjects' and physicians' assessments, the improvement in glabellar lines with Botox was superior to that with placebo at each visit during the 120-day post-injection follow-up period, beginning on day 7 post-injection. The peak effect was seen on day 30 post-injection when 80% of subjects in the two studies combined had the severity of their lines at maximum frown reduced to mild or none, as assessed by their physician, and 89% had at least a moderate (> or =50%) improvement in the appearance of their glabellar lines, as rated by themselves. In a noncomparative extension of these trials, there was a tendency for a higher proportion of subjects to respond to Botox injections after a second and third treatment session. Botox injections for glabellar lines are well tolerated. Headache, the most common adverse event, occurred with a similar frequency to placebo in the two pivotal studies (13% vs 18%). Temporary blepharoptosis occurred in 3.2% of Botox recipients; however, the incidence of this adverse event tended to decrease with repeated treatment sessions. In summary, Botox injections offer a convenient, effective, and well tolerated treatment for improving glabellar frown lines. Repeated injections are necessary to maintain a long-term effect; however, this technique clearly represents an attractive option for individuals who wish to avoid a more major procedure.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14507232     DOI: 10.2165/00128071-200304100-00005

Source DB:  PubMed          Journal:  Am J Clin Dermatol        ISSN: 1175-0561            Impact factor:   7.403


  14 in total

Review 1.  Botulinum toxin in clinical practice.

Authors:  J Jankovic
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-07       Impact factor: 10.154

2.  Anatomical study of the corrugator supercilii muscle and its clinical implication with botulinum toxin A injection.

Authors:  Hun-Mu Yang; Hee-Jin Kim
Journal:  Surg Radiol Anat       Date:  2013-07-30       Impact factor: 1.246

Review 3.  [New botulinum toxins for aesthetic dermatology : A comprehensive review].

Authors:  A Patil; M Kassir; U Wollina; M Goldust
Journal:  Hautarzt       Date:  2021-04-06       Impact factor: 0.751

4.  Frontal branch of the superficial temporal artery: anatomical study and clinical implications regarding injectable treatments.

Authors:  Jae-Gi Lee; Hun-Mu Yang; Kyung-Seok Hu; Young-Il Lee; Hyung-Jin Lee; You-Jin Choi; Hee-Jin Kim
Journal:  Surg Radiol Anat       Date:  2014-05-20       Impact factor: 1.246

5.  Adverse Events Associated With Botox as Reported in a Food and Drug Administration Database.

Authors:  Salma Ahsanuddin; Savannah Roy; Wissam Nasser; Roman Povolotskiy; Boris Paskhover
Journal:  Aesthetic Plast Surg       Date:  2020-10-30       Impact factor: 2.326

Review 6.  OnabotulinumtoxinA (BOTOX®): a review of its use in the prophylaxis of headaches in adults with chronic migraine.

Authors:  James E Frampton
Journal:  Drugs       Date:  2012-04-16       Impact factor: 9.546

7.  Botulinum toxin type A in the healing of chronic lesion following bilateral spasticity of gluteus muscle.

Authors:  Emanuele Cigna; Michele Maruccia; Benedetta Fanelli; Nicolò Scuderi
Journal:  Int Wound J       Date:  2012-10-19       Impact factor: 3.315

8.  Triple-Blind, Prospective, Internally Controlled Comparative Study Between AbobotulinumtoxinA and OnabotulinumtoxinA for the Treatment of Facial Rhytids.

Authors:  Ramtin Kassir; Aparanjita Kolluru; Martin Kassir
Journal:  Dermatol Ther (Heidelb)       Date:  2013-08-16

Review 9.  Cosmetic use of botulinum toxin type A in the elderly.

Authors:  Christine M Cheng
Journal:  Clin Interv Aging       Date:  2007       Impact factor: 4.458

10.  Theories and management of aging: modern and ayurveda perspectives.

Authors:  Hema Sharma Datta; S K Mitra; Rangesh Paramesh; Bhushan Patwardhan
Journal:  Evid Based Complement Alternat Med       Date:  2011-06-08       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.